Tech Center 1600 • Art Units: 1643 1646
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | Non-Final OA | NOVARTIS AG |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | Non-Final OA | Novartis AG |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 17621303 | IN SITU RECRUITMENT, REPROGRAMMING, AND RELEASE OF CAR-T CELLS | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 17751586 | CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF | Final Rejection | Kite Pharma, Inc. |
| 18162955 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF | Final Rejection | Incyte Corporation |
| 18774143 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE | Non-Final OA | Paragon Therapeutics, Inc. |
| 17474389 | Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy | Non-Final OA | INOVIO PHARMACEUTICALS, INC. |
| 18219138 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17950350 | INERT FORMAT | Non-Final OA | GENMAB A/S |
| 17632157 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER | Final Rejection | Astellas Pharma Inc. |
| 18285585 | METHODS FOR THE TREATMENT OF ANAPLASTIC LARGE CELL LYMPHOMA | Non-Final OA | CENTRE HOSPTIALIER UNIVERSITAIRE DE TOULOUSE |
| 18285628 | BISPECIFIC ANTIBODIES TARGETING NKP46 AND GPC3 AND METHODS OF USE THEREOF | Non-Final OA | CYTOVIA THERAPEUTICS, LLC. |
| 18272826 | GARP Protein Antibody and Use Thereof | Non-Final OA | JIANGXI JEMINCARE GROUP CO., LTD. |
| 18278163 | CHIMERIC ANTIGEN RECEPTOR FUSION PROTEIN CO-EXPRESSING IL-7 AND CCR2B, AND APPLICATION THEREOF | Non-Final OA | GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD |
| 18547075 | Anti-Tetranor-PGDM Monoclonal Antibody and Use Thereof | Non-Final OA | Tsuzuki Educational Institute |
| 18044120 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | Non-Final OA | YZTHERAPEUTIC PERFORMANCE LTD. |
| 18051850 | Agents for Treatment of Claudin Expressing Cancer Diseases | Non-Final OA | TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz |
| 17661841 | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) | Non-Final OA | AnaptysBio, Inc. |
| 17622341 | ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR | Non-Final OA | Telix Pharmaceuticals (Innovations) Pty Ltd |
| 17220012 | Detection and Treatment of Malignant Tumours in the CNS | Non-Final OA | Targinta AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy